Clinical Trial Update: Study of Sargramostim in Moderately to Severely Active Crohn's Disease [Phase 2]

View source ↗

Summary

A Phase 2 study of sargramostim for moderately to severely active Crohn's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• sargramostim (sargramostim)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Crohn's Disease | Phase 2 | Status: TERMINATED